that activates a cellular kill switch to eliminate the diseased cell while sparing neighboring healthy tissue. This approach aims to address disease drivers that are considered undruggable by conventional protein-targeting methods. FinalDose initially applies its platform to cancers driven by complex mutations, using established human genetics knowledge to guide target selection and reduce research and validation cycles.